- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Advanced targeted therapies dominate colorectal cancer pipeline
29 September 2015 • Author: Victoria White
A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer.
High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market, finds Frost & Sullivan. To stay competitive, participants are focussing on identifying new targets, enhancing overall survival at the early treatment stage, and reducing toxicity.
New analysis from Frost & Sullivan, Product and Pipeline Analysis of the Global Colorectal Cancer Market, finds that advanced targeted therapies are dominating the colorectal cancer pipeline, accounting for 60% of the drugs under development. This trend remains in line with the broader oncology market’s shift away from standard cytotoxic regimens toward tumour-specific, personalised modalities.
“The growing understanding of the molecular make-up of specific colorectal cancer pathways will lead to the evolution of new biomarker targets and additional multi-targeted immunotherapies,” said Frost & Sullivan Healthcare Senior Industry Analyst Barbara Gilmore. “Biomarker testing, in particular, will become the standard of care, facilitating the selection of a targeted therapy for a patient’s individual need (predictive biomarkers) as well as defining the patient’s specific tumour type (prognostic biomarkers).”
Head-to-head trials now commonplace in the colorectal cancer space
In a crowded market, clear product differentiation and strong marketing efforts will be critical. New solutions must compete with well-established products and therefore, need to demonstrate superior profiles in terms of disease-free survival, time to progression, and overall survival rates. Regulators and payers are intensely scrutinising novel remedies, and the bar for approval and reimbursement is significantly higher than a decade ago.
Moreover, the emergence of value-based reimbursement in United States and Western European healthcare has limited targeted therapeutics and diagnostic biomarker tests to patients who will most likely respond to these costly therapies. Payers want to know which treatments are expected to work in order to justify the high costs of targeted regimens.
“Producing comparative efficacy data that demonstrates improved survival over competing modalities, along with appropriate pricing strategies, is especially vital since there are multiple tiers of treatment,” noted Gilmore. “To that end, head-to-head trials are now commonplace in the colorectal cancer space.”
The rising popularity of targeted therapeutics has not affected cytotoxic use, as physicians administer targeted therapies in combination with cytotoxic treatment. In fact, the far-reaching success of immune-based and targeted modalities points to their potential to finally bridge the gap between present cytotoxic regimens and future cancer treatments.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics